IDEAYA Biosciences, Inc

(NASDAQ:IDYA)

Latest On IDEAYA Biosciences, Inc (IDYA):

Date/Time Type Description Signal Details
2023-05-22 08:40 ESTNewsIdeaya announces FDA nod to run Amgen-sponsored tumor studyN/A
2023-05-16 15:01 ESTNewsIdeaya, Pfizer amend clinical trials supply contacts for darovasertib, Xalkori for eye cancerN/A
2023-05-09 14:24 ESTNewsIDEAYA Biosciences GAAP EPS of -$0.49 beats by $0.03, revenue of $7.88M beats by $2.5MN/A
2023-04-25 18:25 ESTNewsIDEAYA Biosciences up 3%, prices $175M offeringN/A
2023-04-24 19:06 ESTNewsIDEAYA jumps 25% after update on lead programN/A
2023-04-24 19:06 ESTNewsIDEAYA Biosciences to launch $150M common stock offeringN/A
2023-04-24 19:06 ESTNewsIDEAYA announces $150M stock offeringN/A
2023-03-25 03:19 ESTNewsIdeaya Biosciences Has A Strong Pipeline And Looks InvestibleN/A
2023-03-07 20:32 ESTNewsIDEAYA Biosciences GAAP EPS of -$0.50 beats by $0.06, revenue of $4.02M misses by $2.98MN/A
2023-01-23 16:07 ESTNewsIdeaya starts enrolling in mid-stage study of eye cancer drug; combo therapy data update in'23N/A
2023-01-08 17:17 ESTNewsIdeaya Biosciences: Advancing Pipeline, Further Evidence Needed For Immediate EntryN/A
2022-12-12 14:59 ESTNewsIdeaya files with FDA to start trial of IDE161 for solid tumorsN/A
2022-12-05 09:44 ESTNewsIDEAYA wins FDA fast track status for melanoma treatmentN/A
2022-11-08 13:47 ESTNewsIDEAYA Biosciences GAAP EPS of $0.04 beats by $0.66, revenue of $29.7M beats by $23.06MN/A
2022-10-28 02:15 ESTNewsIDEAYA Biosciences a buy at Citi on promise of synthetic lethality for precision oncologyN/A
2022-10-06 12:39 ESTNewsIdeaya Biosciences: Prospects Rebound With Updated Uveal Melanoma DataN/A
2022-09-15 17:26 ESTNewsIDEAYA Biosciences stock slides on pricing ~$80.0M stock offeringN/A
2022-09-14 23:50 ESTNewsIdeaya Biosciences slides 8.5% aftermarket on $80M stock offeringN/A
2022-09-12 19:13 ESTNewsIdeaya says uveal melanoma candidate shrank tumor in 89% of patientsN/A
2022-08-29 13:50 ESTNewsIdeaya wins first milestone in GSK deal as cancer drug reaches clinical trialsN/A
2022-08-15 16:48 ESTNewsIDEAYA Biosciences GAAP EPS of -$0.57 misses by $0.05, revenue of $11.34M beats by $4.75MN/A
2022-08-15 16:48 ESTNewsIdeaya sheds 34% as GSK waives option for cancer candidateN/A
2022-08-15 16:48 ESTNewsIDEAYA downgraded to hold at Stifel after GSK waives development of cancer candidateN/A
2022-07-27 20:18 ESTNewsIDEAYA, Amgen in clinical trial deal for small molecule cancer agentN/A
2022-06-16 20:27 ESTNewsIdeaya: Next 6 Months Critical For Precision Oncology BiotechN/A
2022-05-18 08:24 ESTNewsIdeaya Biosciences price target raised to new Street high at Roth; sees 341% upsideN/A
2022-05-10 07:12 ESTNewsIDEAYA Biosciences GAAP EPS of -$0.36 beats by $0.06, revenue of $11.36M beats by $5.03MN/A
2022-04-28 14:30 ESTNewsIdeaya Biosciences' darovasertib gets FDA orphan drug status to treat rare eye cancerN/A
2022-04-15 00:03 ESTNewsIDEAYA Biosciences (IDYA) Interim IDE397 Phase 1 Clinical Data and Q1 2022 Corporate UpdateN/A
2022-03-20 06:57 ESTNewsIDEAYA Biosciences (IDYA) Investor Presentation - SlideshowN/A
2022-03-16 02:48 ESTNewsIDEAYA Biosciences GAAP EPS of -$0.47 misses by $0.16, revenue of $2.96M misses by $6.02MN/A
2022-03-16 02:47 ESTNewsIDEAYA Biosciences, Inc. 2022 Q1 - Results - Earnings Call PresentationN/A
2022-03-16 02:47 ESTNewsIDEAYA Biosciences, Inc. 2021 Q4 - Results - Earnings Call PresentationN/A
2022-03-16 02:47 ESTNewsIDEAYA Biosciences, Inc. (IDYA) CEO Yujiro Hata on Q4 2021 Results and Interim Clinical Data Update - Earnings Call TranscriptN/A
2022-03-14 12:07 ESTNewsIdeaya, Pfizer ink study pacts for darovasertib/crizotinib combo for eye, liver cancersN/A
2022-03-10 17:23 ESTNewsIdeaya Biosciences upgraded to buy at Stifel on improved risk/reward scenarioN/A
2022-01-31 18:22 ESTNewsIdeaya Bio advances IDE161 into IND-enabling studies for tumorsN/A
2022-01-31 18:22 ESTNewsIdeaya Biosciences (IDYA) Presents at Virtaul Oncology Conference - SlideshowN/A
2022-01-05 22:28 ESTNewsIDEAYA acquires INQUIRE Chemical Library to expand drug discovery platformN/A
2021-12-07 12:10 ESTNewsIDEAYA reports data from Phase 2 darovasertib + crizotinib combo study in uveal melanomaN/A
2021-11-15 06:51 ESTNewsIDEAYA Biosciences EPS beats by $0.01, beats on revenueN/A
2021-10-18 15:50 ESTNewsIDEAYA Biosciences extends losses despite naming new chief scientific officerN/A
2021-09-24 06:20 ESTNewsIDEAYA hit by first hold rating drops over 10% most in over two monthsN/A
2021-08-11 02:37 ESTNewsIDEAYA Biosciences EPS misses by $0.24, misses on revenueN/A
2021-07-21 11:51 ESTNewsIDEAYA Biosciences proposes $80M stock offeringN/A
2021-07-21 11:50 ESTNewsIdeaya secures $80M capital via equity raiseN/A
2021-04-16 14:42 ESTNewsIdeaya's Darovasertib shows encouraging action in metastatic uveal melanomaN/A
2021-04-15 21:08 ESTNewsIdeaya Biosciences initiates dosing in Phase 1 trial for solid tumorsN/A
2021-04-15 21:06 ESTNewsIDEAYA surges after announcing conference call on eye cancer therapyN/A
2021-03-24 00:54 ESTNewsIDEAYA Biosciences EPS beats by $0.04, beats on revenueN/A

About IDEAYA Biosciences, Inc (IDYA):

IDEAYA Biosciences, Inc., an oncology-focused precision medicine company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate is IDE196, a protein kinase C inhibitor that is in Phase 1/2 clinical trial for genetically-defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting MAT2A for solid tumors with MTAP deletions; Pol-theta in tumors with homologous recombination deficiency, including BRCA mutations; PARG in tumors with BRCA2 mutations in base excision repair; and WRN in high microsatellite instability tumors. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase 1/2 study in metastatic uveal melanoma and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

IDYA Quotes by TradingView

See Advanced Chart

General

  • Name IDEAYA Biosciences, Inc
  • Symbol IDYA
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 58
  • Fiscal Year EndDecember
  • IPO Date2019-05-23
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Web URLhttp://www.ideayabio.com
View More

Valuation

  • Forward PE 4.65
  • Price/Sales (Trailing 12 Mt.) 57.39
  • Price/Book (Most Recent Quarter) 3.77
  • Enterprise Value Revenue 51.78
  • Enterprise Value EBITDA 0.31
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Next Quarter EPS Estimate -$0.27
  • Operating Margin -462%
  • Return on Assets -12%
  • Return on Equity -26%
  • Revenue 8.97 million
  • Earnings Per Share -$14.66
  • Revenue Per Share $0.4
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 741.26 million
  • EBITDA -43011000
  • PE Ratio -26.51
  • Analyst Target Price $26
  • Book Value Per Share $6.73
View More

Share Statistics

  • Shares Outstanding 32.18 million
  • Shares Float 16.3 million
  • % Held by Insiders 1364%
  • % Held by Institutions 59.18%
  • Shares Short 708988
  • Shares Short Prior Month 693272
  • Short Ratio 6.46
  • Short % of Float 3%
  • Short % of Shares Outstanding 2%
View More

Technicals

  • 52 Week High $24.53
  • 52 Week Low $3.2
  • 50 Day Moving Average 19.78
  • 200 Day Moving Average 15.25
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

IDEAYA Biosciences, Inc (IDYA) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

IDEAYA Biosciences, Inc (IDYA) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-11-12$8.97 million-$0.17$1.13-115.01%
2020-06-302020-08-12$N/A-$0.59-$0.624.82%
2020-03-312020-05-12$N/A-$0.59-$0.58-2.61%
2019-12-312020-03-24$N/A-$0.53-$0.577.34%
2019-09-302019-11-13$N/A-$0.54-$0.6618.4%
2019-06-302019-08-12$N/A-$0.52-$0.6418.41%
2019-03-312019-05-24$N/A-$0.47

IDEAYA Biosciences, Inc (IDYA) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

IDEAYA Biosciences, Inc (IDYA) Chart:

IDEAYA Biosciences, Inc (IDYA) News:

Below you will find a list of latest news for IDEAYA Biosciences, Inc (IDYA) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

IDEAYA Biosciences, Inc (IDYA) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2024-05-1722.50CALL0 0152.27TRUE00
2024-05-17250CALL0 0132.63TRUE00
2024-05-17300CALL0 0100.34TRUE00
2024-05-17350CALL0 074.92TRUE00
2024-05-17400CALL0 072.17FALSE00
2024-05-17452.5CALL0 362.38FALSE00
2024-05-17502.5CALL0 10FALSE00
2024-05-17551.25CALL0 10FALSE00
2024-05-17601.1CALL0 20FALSE00
2024-05-17650CALL0 00FALSE00
2024-05-1722.50PUT0 00FALSE00
2024-05-17250PUT0 00FALSE00
2024-05-17300PUT0 00FALSE00
2024-05-17350PUT0 089.71FALSE00
2024-05-17403.5PUT6 251.35TRUE0.950.37
2024-05-17450PUT0 068.95TRUE00
2024-05-17500PUT0 0119.88TRUE00
2024-05-17550PUT0 079.7TRUE00
2024-05-17600PUT0 0129.73TRUE00
2024-05-17650PUT0 0137.29TRUE00
2024-06-2122.50CALL0 088.6TRUE00
2024-06-21250CALL0 077.47TRUE00
2024-06-21300CALL0 067.63TRUE00
2024-06-21350CALL0 059.12TRUE00
2024-06-21400CALL0 058.21FALSE00
2024-06-21450CALL0 077.79FALSE00
2024-06-21500CALL0 097.34FALSE00
2024-06-21550CALL0 0111.8FALSE00
2024-06-21600CALL0 00FALSE00
2024-06-2122.50PUT0 00FALSE00
2024-06-21250PUT0 00FALSE00
2024-06-21300PUT0 099.97FALSE00
2024-06-21350PUT0 063.24FALSE00
2024-06-21400PUT0 049.34TRUE00
2024-06-21450PUT0 054.18TRUE00
2024-06-21500PUT0 047.11TRUE00
2024-06-21550PUT0 0110.29TRUE00
2024-06-21600PUT0 0119.8TRUE00
2024-07-191520CALL0 0148.38TRUE00
2024-07-1917.50CALL0 0125.54TRUE00
2024-07-19200CALL0 0106.03TRUE00
2024-07-1922.50CALL0 094.17TRUE00
2024-07-192516.9CALL0 784.18TRUE00
2024-07-193012.31CALL0 170.67TRUE00
2024-07-19358.75CALL0 4764.18TRUE00
2024-07-19405.5CALL0 11864.98FALSE00
2024-07-19455.3CALL0 1461.93FALSE00
2024-07-19502.5CALL0 4170.42FALSE00
2024-07-19550CALL0 088.13FALSE00
2024-07-19601.25CALL0 893.38FALSE00
2024-07-19650.7CALL0 150FALSE00
2024-07-19700.65CALL0 100FALSE00
2024-07-19150PUT0 00FALSE00
2024-07-1917.50PUT0 00FALSE00
2024-07-19200PUT0 00FALSE00
2024-07-1922.50PUT0 00FALSE00
2024-07-19250PUT0 081.38FALSE00
2024-07-19300.8PUT0 1569.46FALSE00
2024-07-19351.25PUT0 355.97FALSE00
2024-07-19403.41PUT0 1052.93TRUE00
2024-07-19458.2PUT86 045.81TRUE8.20
2024-07-19500PUT0 063.2TRUE00
2024-07-19550PUT0 083.82TRUE00
2024-07-19600PUT0 065.65TRUE00
2024-07-19650PUT0 081.14TRUE00
2024-07-19700PUT0 076.72TRUE00
2024-10-1822.50CALL0 081.14TRUE00
2024-10-18250CALL0 075.08TRUE00
2024-10-18300CALL0 070.07TRUE00
2024-10-183510.7CALL0 162.63TRUE00
2024-10-18400CALL0 065.41FALSE00
2024-10-18458.1CALL0 1762.71FALSE00
2024-10-18504.9CALL0 268.69FALSE00
2024-10-18553.5CALL0 665.55FALSE00
2024-10-18603.23CALL0 172FALSE00
2024-10-18651.7CALL0 378.24FALSE00
2024-10-18701.7CALL0 582.16FALSE00
2024-10-1822.50PUT0 097.95FALSE00
2024-10-18250.55PUT0 178.2FALSE00
2024-10-18300PUT0 062.16FALSE00
2024-10-18352.3PUT0 1054.34FALSE00
2024-10-18400PUT0 058.77TRUE00
2024-10-18450PUT0 053.51TRUE00
2024-10-18500PUT0 057.21TRUE00
2024-10-18550PUT0 061.1TRUE00
2024-10-18600PUT0 063.12TRUE00
2024-10-18650PUT0 061.12TRUE00
2024-10-18700PUT0 083.39TRUE00

Latest IDYA Trades:

Date Shares Price
Jun 13, 2022 7:58 PM EST13$10.465
Jun 13, 2022 7:59 PM EST10$10.49
Jun 13, 2022 7:59 PM EST4$10.51
Jun 13, 2022 7:59 PM EST100$10.505
Jun 13, 2022 7:59 PM EST13$10.49

IDEAYA Biosciences, Inc (IDYA) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000092189520001915/0000921895-20-001915-index.htm
2019-02-19UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1676725/000000000019002571/0000000000-19-002571-index.htm
2019-03-27UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1676725/000000000019005947/0000000000-19-005947-index.htm
2019-04-10UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1676725/000000000019006911/0000000000-19-006911-index.htm
2020-06-08UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1676725/000000000020005099/0000000000-20-005099-index.htm
2019-06-07SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1676725/000092189519001764/0000921895-19-001764-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1676725/000092189520000525/0000921895-20-000525-index.htm
2020-06-22SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1676725/000092189520001826/0000921895-20-001826-index.htm
2020-06-223Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000092189520001838/0000921895-20-001838-index.htm
2020-06-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000092189520001839/0000921895-20-001839-index.htm
2020-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000092189520001915/0000921895-20-001915-index.htm
2019-01-17DRSDraft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1676725/000095012319000191/0000950123-19-000191-index.htm
2019-03-15DRS/ADraft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1676725/000095012319002706/0000950123-19-002706-index.htm
2019-03-15DRSLTRCorrespondence Related to Draft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1676725/000095012319002708/0000950123-19-002708-index.htm
2019-04-04DRS/ADraft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1676725/000095012319003031/0000950123-19-003031-index.htm
2019-04-03DRSLTRCorrespondence Related to Draft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1676725/000095012319003032/0000950123-19-003032-index.htm
2019-04-15DRS/ADraft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1676725/000095012319003292/0000950123-19-003292-index.htm
2019-04-15DRSLTRCorrespondence Related to Draft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1676725/000095012319003298/0000950123-19-003298-index.htm
2020-02-13SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1676725/000110465920020293/0001104659-20-020293-index.htm
2016-08-26DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000114036116077947/0001140361-16-077947-index.htm
2018-05-11DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000114036118022864/0001140361-18-022864-index.htm
2019-05-30SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1676725/000114420419028914/0001144204-19-028914-index.htm
2019-04-26S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1676725/000119312519122586/0001193125-19-122586-index.htm
2019-05-01CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1676725/000119312519133212/0001193125-19-133212-index.htm
2019-05-13S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1676725/000119312519144721/0001193125-19-144721-index.htm
2019-05-178-A12BRegistration of securities [Section 12(b)]https://www.sec.gov/Archives/edgar/data/1676725/000119312519150689/0001193125-19-150689-index.htm
2019-05-17S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1676725/000119312519150699/0001193125-19-150699-index.htm
2019-05-20CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1676725/000119312519151714/0001193125-19-151714-index.htm
2019-05-20CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1676725/000119312519151734/0001193125-19-151734-index.htm
2019-05-21S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1676725/000119312519152652/0001193125-19-152652-index.htm
2019-05-24424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1676725/000119312519155710/0001193125-19-155710-index.htm
2019-05-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1676725/000119312519158427/0001193125-19-158427-index.htm
2019-05-28S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1676725/000119312519158497/0001193125-19-158497-index.htm
2019-05-29SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1676725/000119312519158941/0001193125-19-158941-index.htm
2019-08-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1676725/000119312519219009/0001193125-19-219009-index.htm
2019-10-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1676725/000119312519262981/0001193125-19-262981-index.htm
2020-02-06SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1676725/000119312520026298/0001193125-20-026298-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1676725/000119312520038190/0001193125-20-038190-index.htm
2020-04-23SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1676725/000119312520117194/0001193125-20-117194-index.htm
2020-06-01S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1676725/000119312520157312/0001193125-20-157312-index.htm
2020-06-09CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1676725/000119312520164274/0001193125-20-164274-index.htm
2020-06-16424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1676725/000119312520170555/0001193125-20-170555-index.htm
2020-06-18424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1676725/000119312520172625/0001193125-20-172625-index.htm
2020-06-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1676725/000119312520175587/0001193125-20-175587-index.htm
2020-06-30SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1676725/000119312520182578/0001193125-20-182578-index.htm
2020-08-12424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1676725/000119312520217662/0001193125-20-217662-index.htm
2019-05-22CERTCertificationhttps://www.sec.gov/Archives/edgar/data/1676725/000135445719000287/0001354457-19-000287-index.htm
2019-06-10SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1676725/000141057819000348/0001410578-19-000348-index.htm
2019-08-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1676725/000156459019031477/0001564590-19-031477-index.htm
2019-11-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1676725/000156459019043225/0001564590-19-043225-index.htm
2019-11-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1676725/000156459019043230/0001564590-19-043230-index.htm
2019-11-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1676725/000156459019043921/0001564590-19-043921-index.htm
2019-12-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1676725/000156459019046314/0001564590-19-046314-index.htm
2020-01-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1676725/000156459020000927/0001564590-20-000927-index.htm
2020-03-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1676725/000156459020009888/0001564590-20-009888-index.htm
2020-03-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1676725/000156459020011455/0001564590-20-011455-index.htm
2020-03-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1676725/000156459020012306/0001564590-20-012306-index.htm
2020-03-2410-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1676725/000156459020012501/0001564590-20-012501-index.htm
2020-03-24S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1676725/000156459020012528/0001564590-20-012528-index.htm
2020-04-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1676725/000156459020015712/0001564590-20-015712-index.htm
2020-04-27DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1676725/000156459020018814/0001564590-20-018814-index.htm
2020-05-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1676725/000156459020024470/0001564590-20-024470-index.htm
2020-05-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1676725/000156459020024653/0001564590-20-024653-index.htm
2020-06-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1676725/000156459020029421/0001564590-20-029421-index.htm
2020-06-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1676725/000156459020029540/0001564590-20-029540-index.htm
2020-06-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1676725/000156459020031138/0001564590-20-031138-index.htm
2020-08-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1676725/000156459020035722/0001564590-20-035722-index.htm
2020-08-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1676725/000156459020039459/0001564590-20-039459-index.htm
2020-08-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1676725/000156459020039719/0001564590-20-039719-index.htm
2020-09-168-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1676725/000156459020043709/0001564590-20-043709-index.htm
2020-09-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1676725/000156459020044422/0001564590-20-044422-index.htm
2019-05-223Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761919011896/0001567619-19-011896-index.htm
2019-05-223Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761919011897/0001567619-19-011897-index.htm
2019-05-223Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761919011898/0001567619-19-011898-index.htm
2019-05-223Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761919011899/0001567619-19-011899-index.htm
2019-05-223Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761919011901/0001567619-19-011901-index.htm
2019-05-223Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761919011902/0001567619-19-011902-index.htm
2019-05-223Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761919011903/0001567619-19-011903-index.htm
2019-05-223Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761919011904/0001567619-19-011904-index.htm
2019-05-223Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761919011905/0001567619-19-011905-index.htm
2019-05-223Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761919011906/0001567619-19-011906-index.htm
2019-05-223Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761919011907/0001567619-19-011907-index.htm
2019-05-223Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761919011908/0001567619-19-011908-index.htm
2019-05-223Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761919011916/0001567619-19-011916-index.htm
2019-05-233Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761919011927/0001567619-19-011927-index.htm
2019-05-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761919012237/0001567619-19-012237-index.htm
2019-05-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761919012238/0001567619-19-012238-index.htm
2019-05-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761919012279/0001567619-19-012279-index.htm
2019-05-283/AInitial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761919012280/0001567619-19-012280-index.htm
2019-05-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761919012281/0001567619-19-012281-index.htm
2019-05-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761919012282/0001567619-19-012282-index.htm
2019-07-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761919015228/0001567619-19-015228-index.htm
2019-07-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761919015342/0001567619-19-015342-index.htm
2019-07-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761919015483/0001567619-19-015483-index.htm
2019-08-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761919015591/0001567619-19-015591-index.htm
2019-10-113Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761919019493/0001567619-19-019493-index.htm
2019-10-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761919019494/0001567619-19-019494-index.htm
2019-12-193Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761919023452/0001567619-19-023452-index.htm
2019-12-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761919023453/0001567619-19-023453-index.htm
2019-12-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761919023454/0001567619-19-023454-index.htm
2019-12-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761919023455/0001567619-19-023455-index.htm
2019-12-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761919023457/0001567619-19-023457-index.htm
2019-12-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761919023459/0001567619-19-023459-index.htm
2019-12-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761919023460/0001567619-19-023460-index.htm
2020-02-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761920004800/0001567619-20-004800-index.htm
2020-02-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761920004801/0001567619-20-004801-index.htm
2020-02-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761920004803/0001567619-20-004803-index.htm
2020-02-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761920004805/0001567619-20-004805-index.htm
2020-02-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761920004806/0001567619-20-004806-index.htm
2020-04-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761920007287/0001567619-20-007287-index.htm
2020-04-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761920008053/0001567619-20-008053-index.htm
2020-06-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761920011730/0001567619-20-011730-index.htm
2020-06-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761920011852/0001567619-20-011852-index.htm
2020-06-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761920012373/0001567619-20-012373-index.htm
2020-06-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761920012374/0001567619-20-012374-index.htm
2020-06-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761920012375/0001567619-20-012375-index.htm
2020-06-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761920012376/0001567619-20-012376-index.htm
2020-06-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761920012377/0001567619-20-012377-index.htm
2020-06-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761920012387/0001567619-20-012387-index.htm
2020-06-193/AInitial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761920012461/0001567619-20-012461-index.htm
2020-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761920012462/0001567619-20-012462-index.htm
2020-06-303Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761920012699/0001567619-20-012699-index.htm
2020-06-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761920012700/0001567619-20-012700-index.htm
2020-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000156761920012887/0001567619-20-012887-index.htm
2019-05-223Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000172202419000010/0001722024-19-000010-index.htm
2019-05-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1676725/000172202419000012/0001722024-19-000012-index.htm
2019-05-22EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1676725/999999999519001180/9999999995-19-001180-index.htm
2020-06-10EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1676725/999999999520001391/9999999995-20-001391-index.htm
2019-05-24CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1676725/999999999719004844/9999999997-19-004844-index.htm

IDEAYA Biosciences, Inc (IDYA) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of IDEAYA Biosciences, Inc (IDYA). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 1364%
Institutional Ownership: 5918%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-06-04Jason ThroneVP, General CounselSell2,205.008.6619,086.700.00https://www.sec.gov/Archives/edgar/data/1676725/000156761920011852/0001567619-20-011852-index.htm
2020-06-02Mark LacknerSVP, Head of BiologySell104.0010.111,050.960.00https://www.sec.gov/Archives/edgar/data/1676725/000156761920011730/0001567619-20-011730-index.htm
2020-06-16Mark LacknerSVP, Head of BiologySell6,750.0014.93100,760.630.00https://www.sec.gov/Archives/edgar/data/1676725/000156761920012387/0001567619-20-012387-index.htm
2020-06-17Mark LacknerSVP, Head of BiologySell373.0019.917,427.740.00https://www.sec.gov/Archives/edgar/data/1676725/000156761920012387/0001567619-20-012387-index.htm
2019-07-26Paul A. StoneSVP, General CounselBuy10,000.004.6246,200.0010,000.00https://www.sec.gov/Archives/edgar/data/1676725/000156761919015342/0001567619-19-015342-index.htm
2020-06-02Mark LacknerSVP, Head of BiologySell333.009.733,240.79104.00https://www.sec.gov/Archives/edgar/data/1676725/000156761920011730/0001567619-20-011730-index.htm
2019-06-19Jeffrey HagerSVP, Chief Technology OfficerBuy8,628.004.3137,186.68115,511.00https://www.sec.gov/Archives/edgar/data/1676725/000156761919015228/0001567619-19-015228-index.htm
2019-05-285AM Ventures IV, L.P.10% Share HolderBuy10,000.0010.00100,000.00118,521.00https://www.sec.gov/Archives/edgar/data/1676725/000156761919012279/0001567619-19-012279-index.htm
2019-05-28JOHN D DIEKMANDirectorBuy10,000.0010.00100,000.00118,521.00https://www.sec.gov/Archives/edgar/data/1676725/000156761919012282/0001567619-19-012282-index.htm
2019-05-28Paul A. StoneSVP, General CounselBuy10,000.0010.00100,000.00118,521.00https://www.sec.gov/Archives/edgar/data/1676725/000156761919012281/0001567619-19-012281-index.htm
2020-06-19PARTNERS L P/IL BVF10% Share HolderBuy39,052.0014.39561,938.751,196,198.00https://www.sec.gov/Archives/edgar/data/1676725/000092189520001839/0000921895-20-001839-index.htm
2020-06-22PARTNERS L P/IL BVF10% Share HolderBuy7,854.0013.93109,443.131,204,052.00https://www.sec.gov/Archives/edgar/data/1676725/000092189520001839/0000921895-20-001839-index.htm
2020-06-30PARTNERS L P/IL BVF10% Share HolderBuy929.0013.3212,370.941,204,981.00https://www.sec.gov/Archives/edgar/data/1676725/000092189520001915/0000921895-20-001915-index.htm
2019-07-10Jeffrey HagerSVP, Chief Technology OfficerBuy7,145.004.3130,794.95122,656.00https://www.sec.gov/Archives/edgar/data/1676725/000156761919015228/0001567619-19-015228-index.htm
2019-07-26Jeffrey HagerSVP, Chief Technology OfficerBuy5,197.004.3122,399.07127,853.00https://www.sec.gov/Archives/edgar/data/1676725/000156761919015483/0001567619-19-015483-index.htm
2020-03-30Paul A. StoneChief Financial OfficerBuy5,000.004.6223,100.0015,000.00https://www.sec.gov/Archives/edgar/data/1676725/000156761920007287/0001567619-20-007287-index.htm
2020-06-17Paul A. StoneChief Financial OfficerSell600.0019.9511,968.0215,000.00https://www.sec.gov/Archives/edgar/data/1676725/000156761920012462/0001567619-20-012462-index.htm
2020-06-17Paul A. StoneChief Financial OfficerSell2,500.0017.5043,748.7515,600.00https://www.sec.gov/Archives/edgar/data/1676725/000156761920012462/0001567619-20-012462-index.htm
2020-06-19PARTNERS L P/IL BVF10% Share HolderBuy52,443.0014.39754,628.551,655,375.00https://www.sec.gov/Archives/edgar/data/1676725/000092189520001839/0000921895-20-001839-index.htm
2020-06-22PARTNERS L P/IL BVF10% Share HolderBuy10,524.0013.93146,648.781,665,899.00https://www.sec.gov/Archives/edgar/data/1676725/000092189520001839/0000921895-20-001839-index.htm
2020-06-30PARTNERS L P/IL BVF10% Share HolderBuy1,521.0013.3220,254.241,667,420.00https://www.sec.gov/Archives/edgar/data/1676725/000092189520001915/0000921895-20-001915-index.htm
2020-06-17Paul A. StoneChief Financial OfficerBuy3,100.004.6214,322.0018,100.00https://www.sec.gov/Archives/edgar/data/1676725/000156761920012462/0001567619-20-012462-index.htm
2020-06-19PARTNERS L P/IL BVF10% Share HolderBuy6,769.0014.3997,402.53236,040.00https://www.sec.gov/Archives/edgar/data/1676725/000092189520001839/0000921895-20-001839-index.htm
2020-06-22PARTNERS L P/IL BVF10% Share HolderBuy1,354.0013.9318,867.58237,394.00https://www.sec.gov/Archives/edgar/data/1676725/000092189520001839/0000921895-20-001839-index.htm
2020-06-30PARTNERS L P/IL BVF10% Share HolderBuy81.0013.321,078.63237,475.00https://www.sec.gov/Archives/edgar/data/1676725/000092189520001915/0000921895-20-001915-index.htm
2019-05-28TIMOTHY M SHANNONDirectorBuy400,000.0010.004,000,000.002,660,713.00https://www.sec.gov/Archives/edgar/data/1676725/000156761919012238/0001567619-19-012238-index.htm
2019-05-28X L.P. CANAAN10% Share HolderBuy400,000.0010.004,000,000.002,660,713.00https://www.sec.gov/Archives/edgar/data/1676725/000156761919012237/0001567619-19-012237-index.htm
2019-05-285AM Ventures IV, L.P.10% Share HolderBuy240,000.0010.002,400,000.002,844,545.00https://www.sec.gov/Archives/edgar/data/1676725/000156761919012279/0001567619-19-012279-index.htm
2019-05-28JOHN D DIEKMANDirectorBuy240,000.0010.002,400,000.002,844,545.00https://www.sec.gov/Archives/edgar/data/1676725/000156761919012282/0001567619-19-012282-index.htm
2019-05-28Paul A. StoneSVP, General CounselBuy240,000.0010.002,400,000.002,844,545.00https://www.sec.gov/Archives/edgar/data/1676725/000156761919012281/0001567619-19-012281-index.htm
2020-06-17Mark LacknerSVP, Head of BiologyBuy373.004.621,723.26373.00https://www.sec.gov/Archives/edgar/data/1676725/000156761920012387/0001567619-20-012387-index.htm
2020-06-16Mark LacknerSVP, Head of BiologyBuy3,887.004.6217,957.943,887.00https://www.sec.gov/Archives/edgar/data/1676725/000156761920012387/0001567619-20-012387-index.htm
2019-05-28Alexandria Venture Investments, LLC10% Share HolderBuy50,000.0010.00500,000.00432,384.00https://www.sec.gov/Archives/edgar/data/1676725/000172202419000012/0001722024-19-000012-index.htm
2020-06-02Mark LacknerSVP, Head of BiologySell408.008.553,487.38437.00https://www.sec.gov/Archives/edgar/data/1676725/000156761920011730/0001567619-20-011730-index.htm
2019-05-285AM Ventures IV, L.P.10% Share HolderBuy500,000.0010.005,000,000.00500,000.00https://www.sec.gov/Archives/edgar/data/1676725/000156761919012279/0001567619-19-012279-index.htm
2019-07-30Yujiro S HataPresident and CEOBuy15,000.004.3164,650.00610,722.00https://www.sec.gov/Archives/edgar/data/1676725/000156761919015591/0001567619-19-015591-index.htm
2020-04-15Yujiro S HataPresident and CEOBuy47,564.004.31205,000.84658,286.00https://www.sec.gov/Archives/edgar/data/1676725/000156761920008053/0001567619-20-008053-index.htm
2020-06-16Mark LacknerSVP, Head of BiologyBuy2,863.006.9819,983.746,750.00https://www.sec.gov/Archives/edgar/data/1676725/000156761920012387/0001567619-20-012387-index.htm